For financial professionals in Denmark

Keeping perspective on AI’s role in biotech

Portfolio Managers Andy Acker and Agustin Mohedas say artificial intelligence (AI) has the potential to speed drug development, but ultimately, the value of the technology will have to be borne out by clinical data.

Andy Acker, CFA

Andy Acker, CFA

Portfolio Manager

Agustin Mohedas, PhD

Agustin Mohedas, PhD

Portfolio Manager | Research Analyst

15 Jun 2023
3 minute read

Key takeaways:

  • Enthusiasm for AI has spilled into biotech, with numerous accounts of how the advanced technology will revolutionize the sector.
  • But drug development is multifaceted, and some stages of the process, such as regulatory filings and clinical testing, may see limited benefit from AI in the near term.
  • In our view, investors should keep perspective and stay focused on what matters most to the value of biotech companies: approved products backed by clinical data.

The excitement bubbling up around artificial intelligence (AI) has been spilling into the biotech sector, with a steady flow of stories about how AI is helping facilitate drug discovery – from an antibiotic that shows promise against drug-resistant bacteria to a new psoriasis treatment with multibillion-dollar sales potential. These accounts have piqued investor interest given claims that AI can speed drug development, reduce costs, and improve outcomes. In fact, a Morgan Stanley report last year estimated AI and machine learning (a subset of AI) could lead to 50 additional novel drugs worth more than $50 billion in sales over a 10-year period.1

Early signs of AI’s potential

The excitement has some merit. AI is being deployed throughout the sector and showing early signs of its potential. COVID-19 mRNA vaccines, for example, were developed in record time thanks to AI algorithms that helped design synthetic mRNA, identify drug/vaccine targets, and automate quality control steps. In breast cancer screening, AI-based 3D imaging is improving the chances of detecting invasive breast cancer earlier and reducing the number of images radiologists must review. And in a recent report, the Food and Drug Administration said it is seeing a significant increase in drug submissions with AI-based components and expects the number to accelerate from here.2

Keeping perspective

However, as with any new technology, we believe it is important for investors to remember the bottom line. While AI may appear to be accelerating medical breakthroughs, these advances are often rooted in extensive research and development, with AI playing a supporting role. Moderna, which developed one of the mRNA COVID vaccines, spent years fine-tuning synthetic mRNA and collecting and analyzing data that later could be harnessed to fight COVID. And when it comes to drug development, certain time-intensive aspects will be difficult for AI to change drastically. These include clinical development (the phase 1, 2, and 3 clinical trials that test efficacy and safety on patients) and regulatory filings and review, which together can take many years to complete.

Today, it is possible to invest in so-called digital biotech companies that use AI to develop new molecules. And while these firms are making progress in building drug pipelines, it may be many years before the companies bring a therapy to market – even as some of these stocks get lifted by AI enthusiasm.

That said, more tangible progress has been made when it comes to computational tools and methods to help enhance preclinical drug development. Today, the best biotech companies are taking advantage of these tools, benefiting the firms that provide them.

In short, we believe AI has an important future in biotech, with the potential to speed drug discovery and facilitate effective and targeted treatments for patients. But ultimately, the value of firms behind the technology will be derived from the products created – the success of which depends on clinical data that will take years to produce. Until such data are available, we believe investors should approach AI in biotech with caution.

1 Morgan Stanley, “Why Artificial Intelligence Could Speed Drug Discovery,” 9 September 2022.
2 U.S. Food and Drug Administration, “Using artificial Intelligence & Machine Learning in the Development of Drug & Biological Products,” 16 May 2023.

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.


Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.


The information in this article does not qualify as an investment recommendation.


Marketing Communication.






The Janus Henderson Horizon Fund (the “Fund”) is a Luxembourg SICAV incorporated on 30 May 1985, managed by Janus Henderson Investors Europe S.A. Janus Henderson Investors Europe S.A. may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation. This is a marketing communication. Please refer to the prospectus of the UCITS and to the KIID before making any final investment decisions.
    Specific risks
  • Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates.
  • When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies.
  • Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
  • The Fund may incur a higher level of transaction costs as a result of investing in less actively traded or less developed markets compared to a fund that invests in more active/developed markets. These transaction costs are in addition to the Fund's Ongoing Charges.
  • The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.